Investments Opinions The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. By EQUITY INSIDER Jul 15, 2026 Issued on behalf of Conexeu Sciences Inc.
Investments Opinions The GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It. By EQUITY INSIDER Jul 15, 2026 Issued on behalf of Conexeu Sciences Inc.
Investments Opinions The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts By EQUITY INSIDER Jun 2, 2026 Issued on behalf of Conexeu Sciences Inc.
Investments Opinions The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts By EQUITY INSIDER Jun 2, 2026 Issued on behalf of Conexeu Sciences Inc.